SAN FRANCISCO, April 18, 2016 -- Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm reminds Hortonworks, Inc. (NASDAQ:HDP) investors there is an April 29, 2016 lead plaintiff deadline in a securities fraud class action lawsuit regarding its misrepresentations to investors and failure to disclose lack of adequate cash.
If you suffered significant losses because of your purchases of HDP between November 4, 2015 and January 15, 2016, or have information that will help our investigation contact Hagens Berman Partner Reed Kathrein, who is leading the firm’s investigation by calling 510-725-3000, emailing [email protected] or visiting https://www.hbsslaw.com/cases/HDP. The lawsuit was filed in the U.S. District Court for the Northern District of California and investors have until April 29, 2016 to move the court to participate as a lead plaintiff.
The lawsuit filed against Hortonworks states that the company issued materially false and misleading statements about its capital. According to the suit, Hortonworks misrepresented that it had sufficient cash and cash equivalents to fund 12 months of working capital and capital expenditure needs and failed to disclose that actually lacked adequate cash to meet those working capital and capital expenditure requirements over that period of time. The suit also states that Hortonworks failed to disclose that, as a result, the Company was contemplating a significant offering to fund its operations.
On Friday, January 15, 2016, post-market, Hortonworks announced it retained Goldman Sachs to raise $100 million in a secondary offering. In response, one analyst stated, “…it will be incumbent on HDP during its roadshow to show why this offering, announced in this way, at this time, should not be interpreted as evidence of serious difficulty.”
When the truth about the Company's operations was revealed on January 15, 2016, the price of HDP stock price declined $6.13 or nearly 37%, to close at $10.44 on January 19, 2016, the next trading day.
Whistleblowers: Persons with non-public information regarding Hortonworks, Inc. should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
Hagens Berman is headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000


California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Italy Fines Apple €98.6 Million Over App Store Dominance
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 



